



**Attention-Deficit/Hyperactivity Disorder (ADHD)  
Project Story Board**

**Waterman Pediatrics/Coastal Medical, Inc.**  
Team Members: Susan Royal, Carla Porter, Aleah George,  
Sarah Thompson, Putney Pyles, Beth Lange

**PLAN**

**Aim Statement**

To safeguard the process for writing stimulant prescriptions in our office, we will increase the number of patients with a signed controlled substance prescription contract from 0% to 50% by March 9, 2017.

**Problem**

In this era of increasing abuse of controlled substances, it is important to have a contract with our patients that specifically details the rights, responsibilities and expectations of controlled substance prescriptions in our office.

**Goals**

1. To foster an office culture that understands the importance of obtaining signed controlled substance agreements on every eligible patient.
2. To develop a non-disruptive work flow that incorporates obtaining the signed controlled substance agreement without adding time or stress to the office exchange
3. To develop a communication strategy with patients that explains the necessity of these new forms
4. To obtain the signed controlled substance agreements on eligible patients

**DO**

**Key Measures**

The number of unique Waterman patients with a stimulant prescription in the medication list who have a signed controlled substance agreement listed in their problem list or history of present illness section of the electronic record

**Methods**

1. To develop work flows to obtain signed CSAs for patients newly starting stimulant medications, patients refilling their stimulant medication in face-to-face office visit, and patients refilling their stimulant medications not face-to-face (mail or pick up prescription)
2. To develop a structured data field in the patient chart to note the presence of a signed CSA.
3. To create a data mine for those patients with a stimulant medication listed in their medication list (denominator) and the number of those patients who have signed CSAs in their chart (numerator).


**STUDY**

**Outcomes/Results**

After initially achieving rapid gains in signed CSAs, the numbers plateaued in the winter quarter.

Theoretical causes for this include - disruptive work flows due to holiday vacations and increased winter illness season as well as less prescriptions written this quarter.

We assessed only for internal causes when indeed there was an external process influence as well - the pharmacy team's work flow for adjudicating the signed CSAs. By neutralizing this variable, the corrected last quarter data shows continued improvement.



**ACT**

**Next Steps**

To work with staff and clinicians to reassess the current workflow with the continued goal of obtaining signed controlled substance agreements on the majority of our patients whose stimulant medication prescriptions are written in our office.